Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has announced that its CEO, Seth Lederman, M.D., will present at the prestigious 2025 BIO International Convention in Boston. This presentation, scheduled for June 16 at 5:00 p.m. in Room 153B, underscores the company's commitment to addressing critical health challenges through innovative therapies.
The company is on the verge of submitting a New Drug Application to the U.S. Food and Drug Administration for TNX-102 SL, a promising treatment for fibromyalgia that has shown significant results in phase 3 studies. With Fast Track designation from the FDA, TNX-102 SL represents a potential breakthrough in pain management. Additionally, Tonix's contract with the U.S. Department of Defense to develop TNX-4200 highlights its role in enhancing medical readiness against biological threats.
Tonix's diverse portfolio, including treatments for CNS disorders, organ transplant rejection, and rare diseases, positions it as a leader in biopharmaceutical innovation. The upcoming presentation at the BIO International Convention offers a platform to share these advancements with the global health community, signaling important progress in treating complex conditions and improving patient outcomes.
